title: Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein.
abstract: Tuberculosis continues to ravage humanity, killing 2 million people yearly. Most cases occur in areas of the world to which the disease is endemic, where almost everyone is vaccinated early in life with Mycobacterium bovis BCG, the currently available vaccine against tuberculosis. Thus, while more-potent vaccines are needed to replace BCG, new vaccines are also needed to boost the immune protection of the 4 billion people already vaccinated with BCG. Until now, no booster vaccine has been shown capable of significantly enhancing the level of protective immunity induced by BCG in the stringent guinea pig model of pulmonary tuberculosis, the "gold standard" for testing tuberculosis vaccines. In this paper, we describe a booster vaccine for BCG comprising the purified recombinant Mycobacterium tuberculosis 30-kDa protein, the major secreted protein of this pathogen. In the guinea pig model of pulmonary tuberculosis, boosting BCG-immunized animals once with the 30-kDa protein greatly increased cell-mediated and humoral immune responses to the protein in three consecutive experiments. Most importantly, boosting BCG-immunized animals once with the 30-kDa protein significantly enhanced protective immunity against aerosol challenge with highly virulent M. tuberculosis, as evidenced by a significantly reduced lung and spleen burden of M. tuberculosis compared with those for nonboosted BCG-immunized animals (mean additional reduction in CFU of 0.4 +/- 0.1 log in the lung [P = 0.03] and 0.6 +/- 0.1 log in the spleen [P = 0.002]). This study suggests that administering BCG-immunized people a booster vaccine comprising the 30-kDa protein may enhance their level of immunoprotection against tuberculosis.
authors.affiliation: Dept. of Medicine, CHS 37-121, School of Medicine, University of California, Los Angeles, 10833 Le Conte Ave., Los Angeles, CA 90095-1688, USA. mhorwitz@mednet.ucla.edu
authors.forename: Marcus A
authors.initials: MA
authors.lastname: Horwitz
authors.forename: Günter
authors.initials: G
authors.lastname: Harth
authors.forename: Barbara Jane
authors.initials: BJ
authors.lastname: Dillon
authors.forename: Sasa
authors.initials: S
authors.lastname: Maslesa-Galic
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000276:immunology*; D001500:BCG Vaccine / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D001835:Body Weight / Q000276:immunology; D006168:Guinea Pigs; D007117:Immunization, Secondary; D013997:Time Factors; D014376:Tuberculosis / Q000276:immunology / Q000517:prevention & control*
chemical_list: D001500:BCG Vaccine; D001426:Bacterial Proteins; C030960:tuberculoprotein, Mycobacterium tuberculosis